ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Conditions: Breast Carcinoma Interventions: Combination Product: Endocrine therapy; Combination Product: Endocrine therapy combined with the local treatment of FES-negative lesions; Combination Product: Chemotherapy Sponsors: Institut Curie; Zionexa Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Endocrine Therapy | HER2 | Research